Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.91 |
| ▸ | ARG2 | P78540 | 4/20 | 0.55 |
| ▸ | ARG1 | P05089 | 3/20 | 0.55 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.54 |
| ▸ | NOS2 | P35228 | 6/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 4/20 | 0.53 |
| ▸ | NOS3 | P29474 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL4641859 | 1.00 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL31644218 | 1.00 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL31039861 | 1.00 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL8937983 | 0.98 | GSR (0.87) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL15286920 | 0.95 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL1042282 | 0.95 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL9439278 | 0.95 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL12867528 | 0.95 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL7343 | 0.95 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL8613373 | 0.95 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117479946-A | Dry powder compositions containing treprostinil and its prodrug and further comprising (E) -3,6-bis [4- (N-carbonyl-2-propenyl) amide butyl ] -2,5-diketopiperazine (FDKP) | 联合治疗公司 | 2024-01-30 | — | — | CN | claimed |
| EP-3727600-B1 | AMINO ACID CARBAMATE COMPLEXES | COLGATE PALMOLIVE CO (US) | 2023-09-20 | — | — | EP | claimed |
| US-10857083-B2 | Amino acid carbamate complexes | COLGATE-PALMOLIVE COMPANY (US) | 2020-12-08 | — | — | US | claimed |
| EP-3727600-A1 | AMINO ACID CARBAMATE COMPLEXES | Colgate-Palmolive Company (US) | 2020-10-28 | — | — | EP | claimed |
| CN-111479614-A | Amino acid carbamate complexes | 高露洁-棕榄公司 | 2020-07-31 | — | — | CN | claimed |
| US-20190183765-A1 | Amino Acid Carbamate Complexes | COLGATE-PALMOLIVE COMPANY (US) | 2019-06-20 | — | — | US | claimed |
| CN-1213058-C | FAP-activated anti-tumor compounds | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-08-03 | — | — | CN | claimed |
| EP-1439820-A2 | METHODS AND DOSAGE FORMS FOR IMPROVING THE BIOAVAILABILITY OF THERAPEUTIC AGENTS | LABOPHARM INC. (CA) | 2004-07-28 | — | — | EP | claimed |
| US-20030138486-A1 | Methods and dosage forms for improving the bioavailability of therapeutic agents | KING PHARMACEUTICALS RESEARCH | 2003-07-24 | — | — | US | claimed |
| WO-2003037301-A2 | ORAL DOSAGE FORMS FOR IMPROVING THE BIOAVAILABILITY OF THERAPEUTIC AGENTS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC (US) | 2003-05-08 | — | — | WO | claimed |
| WO-2003037296-A2 | METHODS AND DOSAGE FORMS FOR IMPROVING THE BIOAVAILABILITY OF THERAPEUTIC AGENTS | LABOPHARM INC. (CA) | 2003-05-08 | — | — | WO | claimed |
| EP-0162043-B1 | METHOD AND APPARATUS FOR PRODUCING EFFERVESCENT TABLETS AND GRANULATED PRODUCTS | BRU, Jean (FR) | 1989-12-13 | — | — | EP | claimed |
| US-4614648-A | Process for manufacturing effervescent granules and tablets | BRU JEAN (FR) | 1986-09-30 | — | — | US | claimed |
| CN-117479946-A | Dry powder compositions containing treprostinil and its prodrug and further comprising (E) -3,6-bis [4- (N-carbonyl-2-propenyl) amide butyl ] -2,5-diketopiperazine (FDKP) | 联合治疗公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-3727600-B1 | AMINO ACID CARBAMATE COMPLEXES | COLGATE PALMOLIVE CO (US) | 2023-09-20 | — | — | EP | disclosed |
| US-11739055-B2 | Process for preparing diisocyanates based on lysine | EVONIK OPERATIONS GMBH (DE) | 2023-08-29 | — | — | US | disclosed |
| WO-2003037301-A2 | ORAL DOSAGE FORMS FOR IMPROVING THE BIOAVAILABILITY OF THERAPEUTIC AGENTS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC (US) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003037296-A2 | METHODS AND DOSAGE FORMS FOR IMPROVING THE BIOAVAILABILITY OF THERAPEUTIC AGENTS | LABOPHARM INC. (CA) | 2003-05-08 | — | — | WO | disclosed |
| US-RE33086-E | HIGH PURITY; FOR PHARMACEUTICALS | RECHERCHE ET PROPRIETE INDUSTRIELLE (FR) | 1989-10-10 | — | — | US | disclosed |
| US-4614648-A | Process for manufacturing effervescent granules and tablets | BRU JEAN (FR) | 1986-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739055-B2 | Process for preparing diisocyanates based on lysine | KDM7A, KDM8, JMJD6 | GSR 2994/4885ARG2 328/4885ARG1 50/4885 |
| US-10857083-B2 | Amino acid carbamate complexes | CPS1, GLUL, PROC | GSR 1816/4885ARG2 57/4885ARG1 27/4885 |
| US-20190183765-A1 | Amino Acid Carbamate Complexes | CPS1, GLUL, PROC | GSR 1816/4885ARG2 57/4885ARG1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.